Skip to Content

Cancer Treatment Startup Based on U Research Wins Tekne Award

picture of award

A startup company that develops next-generation cancer treatments based on University of Minnesota research has been awarded for its innovative therapies.

GeneSegues Therapeutics received the Minnesota High Tech Association’s Tekne Award Wednesday night in the category of Health Care — Small and Growing. Tekne Awards recognize innovation across Minnesota in industries ranging from advanced manufacturing, health care and agricultural technology.

GeneSegues develops microscopic capsules that serve as a vessel to transport gene therapies through the body that help stop the spread of cancer. The capsules are smaller than conventional nanoparticles, allowing them to slip past the human body’s biological barriers and attack cancerous cells more precisely, while leaving healthy cells unharmed.

The company grew out of research done by U of M post-doc Gretchen Unger, Ph.D., in the early 2000s. Unger is currently chief scientific officer with the company. The company’s CEO is Laura Brod, who is also an at-large member of the University’s Board of Regents.

Kevin Coss

Kevin Coss

Kevin is a communications specialist with the Office of the Vice President for Research.

coss@umn.edu

Latest Blog Posts

John Little

PhD student John Little explores Native American veterans’ experiences during and after the war to provide new perspectives on this piece of history.

Read More
Building Detail: carved figures above door

Two projects are awarded neary $500,000 from the Minnesota Futures Grant Program.

Read More
Exterior of Snyder Hall

Recipients of OVPR's 2019 Research Infrastructure Investment Program announced.

Read More
Birthday cake with the word "Inquiry" atop

Launched in June 2014, Inquiry was created to explore U of M research and innovation across centers, institutes, colleges, departments, and campuses.

Read More
Categories: